In addition, first reports on early phase clinical trials with TRAIL-receptors targeting compounds in CRC showed disappointing results, prompting further investigation on a possible role of the receptors for TRAIL as therapeutic target in this tumor. The gene discussed is TNFSF10; the disease is neoplasm.